| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers O > Headlines for Oncolytics Biotech Inc. > News item |
Oncolytics with National Cancer Institute solicit clinical trials for cancer treatment Reolysin
By E. Janene Geiss
Philadelphia, Jan. 18 - Oncolytics Biotech Inc. said Wednesday that the Cancer Therapy Evaluation Program, part of the U.S. National Cancer Institute, has issued a solicitation for letters of intent with respect to the conduct of two human clinical trials using Reolysin, a proprietary formulation of the human reovirus being developed as a potential cancer therapeutic.
The program is soliciting proposals for a phase 2 study of Reolysin administered systemically in patients with melanoma, according to a company news release.
The dosage and dosing regimen to be used in the study will be determined based on data derived from ongoing U.K. and U.S. phase 1 systemic administration studies being conducted by Oncolytics, officials said.
The program also is soliciting proposals for a phase 1/2 study of Reolysin co-administered both systemically and intraperitoneally in patients with ovarian cancer.
The purpose of the phase 1 portion of the trial is to determine the maximum tolerated dose of Reolysin given by intraperitoneal administration in combination with a constant systemic dose and dosing regimen, officials said.
Oncolytics will provide Reolysin for all clinical trials conducted and sponsored by the National Cancer Institute under a clinical trials agreement.
The National Cancer Institute initially approved Reolysin for collaborative development after an analysis of preclinical, GLP toxicology and clinical data. Since the clinical trials agreement was approved, Oncolytics and the National Cancer Institute have worked together to select cancer indications and suitable development programs, officials said.
Oncolytics is a Calgary, Alta., biotechnology company focused on the development of Reolysin, its proprietary formulation of the human reovirus, as a potential cancer therapeutic.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.